[Skip to Navigation]
Sign In
September 2011

Comparative Efficacy and Safety of 4 Randomized Regimens to Treat Early Pseudomonas aeruginosa Infection in Children With Cystic Fibrosis

Author Affiliations
    † Deceased.

Author Affiliations: Departments of Anesthesiology and Pain Medicine (Dr Treggiari) and Pediatrics (Drs Mayer-Hamblett, Gibson, Burns, Rosenfeld, and Ramsey), Seattle Children's Hospital (Mr Khan and Ms Williams), and Department of Biostatistics, University of Washington (Dr Kronmal), Seattle; Department of Pediatrics, University of North Carolina, Chapel Hill (Dr Retsch-Bogart); Department of Probability and Statistics, Charles University, Prague, Czech Republic (Dr Kulich); Department of Pediatrics, Baylor College of Medicine, Houston, Texas (Dr Hiatt); Department of Pediatrics, Children's Hospital Boston, Boston, Massachusetts (Dr Spencer); Department of Pediatrics, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (Dr Orenstein); Department of Pediatrics, University of Utah, Salt Lake City (Dr Chatfield); and Department of Pediatrics, University of Virginia, Charlottesville (Dr Froh).

Arch Pediatr Adolesc Med. 2011;165(9):847-856. doi:10.1001/archpediatrics.2011.136

Objective  To investigate the efficacy and safety of 4 antipseudomonal treatments in children with cystic fibrosis with recently acquired Pseudomonas aeruginosa infection.

Design  Randomized controlled trial.

Setting  Multicenter trial in the United States.

Participants  Three hundred four children with cystic fibrosis aged 1 to 12 years within 6 months of P aeruginosa detection.

Interventions  Participants were randomized to 1 of 4 antibiotic regimens for 18 months (six 12-week quarters) between December 2004 and June 2009. Participants randomized to cycled therapy received tobramycin inhalation solution (300 mg twice a day) for 28 days, with oral ciprofloxacin (15-20 mg/kg twice a day) or oral placebo for 14 days every quarter, while participants randomized to culture-based therapy received the same treatments only during quarters with positive P aeruginosa cultures.

Main Outcome Measures  The primary end points were time to pulmonary exacerbation requiring intravenous antibiotics and proportion of P aeruginosa –positive cultures.

Results  The intention-to-treat analysis included 304 participants. There was no interaction between treatments. There were no statistically significant differences in exacerbation rates between cycled and culture-based groups (hazard ratio, 0.95; 95% confidence interval [CI], 0.54-1.66) or ciprofloxacin and placebo (hazard ratio, 1.45; 95% CI, 0.82-2.54). The odds ratios of P aeruginosa– positive culture comparing the cycled vs culture-based group were 0.78 (95% CI, 0.49-1.23) and 1.10 (95% CI, 0.71-1.71) comparing ciprofloxacin vs placebo. Adverse events were similar across groups.

Conclusions  No difference in the rate of exacerbation or prevalence of P aeruginosa positivity was detected between cycled and culture-based therapies. Adding ciprofloxacin produced no benefits.

Trial Registration  ClinicalTrials.gov Identifier: NCT00097773.


Pseudomonas aeruginosa, the predominant pathogen associated with chronic infection in cystic fibrosis (CF),1 results in more rapid decline in lung function, increased hospitalization, and decreased survival2,3 starting in the first decade of life.1,4-16 Several randomized trials16-19 and a cohort study20 demonstrated that inhaled antibiotics (colistin or tobramycin) with or without oral fluoroquinolones may result in prolonged eradication of early (nonchronic) P aeruginosa acquisition.16,21,22 Although spontaneous clearance may occur in some patients,18,19 data suggest that antibiotics might be superior to no treatment.23 Based on these data, aggressive antibiotic treatment at initial P aeruginosa airway detection has been recommended using a range of antibiotic strategies and treatment duration.24-26

It remains unclear whether clearance of P aeruginosa from airway cultures has any impact on other health indicators such as exacerbation of respiratory symptoms (pulmonary exacerbation [PE]27), lung function, hospitalization, and growth.28 While there is potential to benefit from early intervention, concerns remain regarding the risks of long-term antibiotic exposure and selection of resistant bacterial pathogens.29

Quiz Ref IDWe compared the clinical and microbiological effectiveness as well as the safety of 4 antibiotic treatment strategies for newly identified P aeruginosa infection isolated from respiratory cultures in children with CF.30 We hypothesized that more frequent administration and double antibiotic therapy would result in reduced rates of PE and frequency of P aeruginosa– positive respiratory cultures over an 18-month study period. We report herein the results of the largest randomized controlled trial of antibiotic therapies to treat P aeruginosa detection ever conducted in young children with CF.


We conducted a multicenter, randomized trial of young children with CF at the time of new isolation of P aeruginosa in respiratory tract cultures. Eligible participants were recruited at 55 Cystic Fibrosis Foundation–accredited clinical centers throughout the United States (see “EPIC Participating Centers and Investigators” box). The duration of study participation was 18 months. All centers obtained institutional review board approval, and all participants' parent or legal guardian provided informed consent. Details of the study design are presented elsewhere.30


Quiz Ref IDMale and female subjects 1 year or older and 12 years or younger with a diagnosis of CF31 with a documented respiratory tract culture positive for P aeruginosa within the 6 months prior to randomization were eligible. New isolation of P aeruginosa was defined as the first lifetime documented respiratory positive culture or as a positive culture after at least a 2-year absence of P aeruginosa growth. Among participants aged 12 to 15 months, at least 1 P aeruginosa– positive respiratory culture since birth was required. No more than 1 course of inhaled or intravenous antipseudomonal therapy was allowed prior to baseline. Additional detailed eligibility criteria have been previously reported.30


Quiz Ref IDParticipants were equally randomized to 1 of 4 antipseudomonal treatment algorithms (eTable 1): (1) scheduled antimicrobial therapy consisting of tobramycin inhalation solution (TIS) combined with oral ciprofloxacin every 3 months (cycled TIS and oral ciprofloxacin); (2) scheduled TIS combined with oral placebo every 3 months (cycled TIS and oral placebo); (3) TIS combined with oral ciprofloxacin only when quarterly respiratory cultures were found positive for P aeruginosa (culture-based TIS and oral ciprofloxacin); and (4) TIS combined with oral placebo only when quarterly respiratory cultures were found positive for P aeruginosa (culture-based TIS and oral placebo). The antimicrobial therapy administered during treatment cycles was open-label TIS (TOBI), 300 mg twice a day for 28 days, and either oral ciprofloxacin (Cipro), 15 to 20 mg/kg/dose up to 750 mg/dose twice a day, or oral placebo for 14 days. A 14-day ciprofloxacin course was chosen to minimize the emergence of P aeruginosa resistance.32,33 At the beginning of the study, all participants received an initial treatment cycle according to their assigned group and a second consecutive 28-day course of TIS monotherapy if respiratory cultures sampled during the third week of the first antipseudomonal cycle remained P aeruginosa positive (eTable 1).


Participants had study visits at the time of randomization, 3 weeks later, and then quarterly for a total of 18 months.30 Oropharyngeal swabs, or sputum cultures, if available, were obtained at each study visit. Semiquantitative bacterial cultures were processed at a central microbiology laboratory.34 All P aeruginosa isolates were assessed for mucoid phenotype, and antibiotic susceptibility testing of all CF pathogens was performed.30 Cultures sampled for clinical indications and processed at local laboratories were not included in the evaluation of the microbiological study end points. As part of the physical examination, participants had a standardized musculoskeletal assessment to monitor ciprofloxacin toxic effects. Nutritional assessment included length (children ≤18 months) or height and weight. Spirometry data were collected in subjects 4 years or older who were able to perform the procedure.35 Age-appropriate audiometric testing was performed at 40 selected sites with the capability of performing the testing. Laboratory studies to assess safety included measurement of serum creatinine and serum urea nitrogen levels, liver function, and a complete blood cell count at baseline and every 6 months.


The primary clinical end point was the time to first PE requiring intravenous antibiotics or hospital admission during the 18-month study period. Since there is no validated definition of exacerbation in patients this age, we used an a priori–developed definition.30 The primary microbiological end point was the proportion of P aeruginosa –positive respiratory cultures among all quarterly cultures obtained after the initial treatment cycle.

Secondary clinical efficacy end points included (1) time to PE requiring any (intravenous, inhaled, or oral) antibiotic use or hospitalization, (2) anthropometric measures (linear growth, weight gain), and (3) pulmonary function test results (forced vital capacity, forced expiratory flow, and forced expiratory volume in 1 second). Evaluation of the safety profiles included adverse events, musculoskeletal symptoms, hearing acuity, hematological profile, and renal and liver function. In addition, emergence of antibiotic-resistant P aeruginosa and other significant pathogens was monitored.


The sample size for the clinical efficacy end point (time to first PE requiring intravenous antibiotics or hospitalization) was estimated based on the annual exacerbation event rate reported in the 1985-2000 Cystic Fibrosis Foundation National Patient Registry.30 There was a 50% difference in the annual exacerbation rate between children with new-onset P aeruginosa infection (0.36 per person-year) and children never infected with P aeruginosa (0.18 per person-year). A reduction in the exacerbation rate with more aggressive antibiotic therapy from 0.36 to 0.18 per person-year was assumed to be clinically meaningful. An 18-month study with 300 patients had 80% power to detect at least a 40% reduction in the risk of exacerbation in the cycled group as compared with the culture-based treatment group (primary comparison of interest) at the 2-sided α level of 5%. The design of this study also allowed comparisons between participants who received ciprofloxacin vs those who received placebo. Treatment interaction between cycled therapy and ciprofloxacin was also tested.


The randomization code was developed using a computer random-number generator to assign treatments within permuted blocks of size 12. Randomization assignment was available at the sites via an interactive voice response system with e-mail confirmation of the treatment assignment. Children remained on the same allocation throughout the study.

All study personnel and participants were blinded to oral therapy assignment but not to cycled or culture-based treatment allocation. The core study investigators were blinded to all treatment allocation for the entire study.


The intention-to-treat population was used for the primary efficacy and safety analyses (Figure 1). There was no imputation for missing values in secondary analyses and complete case analysis was performed. The censored failure time for the primary clinical efficacy analysis was the date of PE diagnosis, or the end of follow-up if no PE had occurred.30

Figure 1. Flow diagram of participants through each stage of the randomized trial. *One adverse event resulting in withdrawal was due to skin rash attributed to ciprofloxacin.

Figure 1. Flow diagram of participants through each stage of the randomized trial. *One adverse event resulting in withdrawal was due to skin rash attributed to ciprofloxacin.

Hazard ratios and 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression, with covariate adjustment for baseline age group (1-3, >3-6, and >6 years). The age group–adjusted odds ratios (ORs) of a P aeruginosa– positive culture and 95% CI were estimated using generalized estimating equations with robust variance, specifying a logit link and assuming an independence working correlation structure.30

There was no interaction between cycled therapy and ciprofloxacin for the main study end points. Thus, the 2 main evaluations including cycled vs culture-based therapy and oral ciprofloxacin vs oral placebo are presented.

In secondary analyses, we evaluated time to PE requiring any antibiotics or hospitalization. Differences between groups in the linear rate of change from baseline in height and weight and spirometry results were tested using repeated-measures regression with robust variance estimation, with covariate adjustment for baseline age group.36 Differences in proportions were tested using a 2-sample test of proportions. Adverse events were descriptively summarized using the Medical Dictionary for Regulatory Activities system organ class and preferred term.

For all analyses, a 2-sided significance level of .05 was used without adjustment for multiple comparisons. All analyses were performed using the statistical software SAS version 9.1.3 (SAS Institute Inc, Cary, North Carolina) or R statistical package version 2.9.1 (R Foundation for Statistical Computing, Vienna, Austria).


Enrollment, conduct, and safety outcomes were monitored throughout the study by a Data and Safety Monitoring Board (see “EPIC Participating Centers and Investigators” box), with a formal safety report reviewed every 6 months.



A total of 337 children were screened for inclusion from December 2004 to February 2008 and 304 participants were randomized equally (n = 76) to each of the 4 treatment algorithms, received at least 1 dose of study drug (Figure 1), and were included in the intention-to-treat analysis. The follow-up was completed in June 2009. Over the study period, 3 to 8 participants withdrew from each treatment group (Figure 1). Follow-up visit completion, sample collection, and compliance with study medications were 90% or greater across treatment groups.


Participant baseline characteristics were well balanced across groups, including genotype status (Table 1 and eTable 2). All participants had a P aeruginosa– positive culture within 6 months prior to randomization (week 0), and 46% received antimicrobial therapy during the 6 months preceding enrollment. At the time of randomization, 295 participants had a viable respiratory microbiology culture, with 118 (40%) P aeruginosa positive and 170 (58%) positive for Staphylococcus aureus (Table 1).

Table 1. Participant Baseline Characteristics by Treatment Group
Participant Baseline Characteristics by Treatment Group


Following the first treatment cycle, the cycled and culture-based groups differed in treatment frequency during the study (Figure 2).

Figure 2. Percentage of participants prescribed treatment in the cycled and culture-based therapy groups.

Figure 2. Percentage of participants prescribed treatment in the cycled and culture-based therapy groups.


Quiz Ref IDOverall, 24 of 152 (16%) in the cycled therapy group and 26 of 152 (17%) in the culture-based group experienced a PE requiring intravenous antibiotics or hospitalization. The hazard ratio (HR) of PE comparing cycled with culture-based therapy was 0.95 (95% CI, 0.54-1.66) (P = .86) (Figure 3A). Twenty-nine of 152 (19%) in the ciprofloxacin group and 21 of 152 (14%) in the placebo group experienced a PE requiring intravenous antibiotics or hospitalization (HR of PE, 1.45; 95% CI, 0.82-2.54; P = .20) (Figure 3B). Overall, the proportion of P aeruginosa– positive cultures was on average less than 20%. No statistically significant differences were seen in the odds of a P aeruginosa– positive culture comparing the cycled vs culture-based group (OR, 0.78; 95% CI, 0.49-1.23; P = .28) (Figure 3C) or the ciprofloxacin vs placebo group (OR, 1.10; 95% CI, 0.71-1.71; P = .67) (Figure 3D).

Figure 3. Efficacy outcomes. A, Proportion of participants remaining free of exacerbations requiring intravenous antibiotics or hospitalization over time, comparing participants who received cycled therapy (n = 152) with participants who received culture-based therapy (n = 152). B, Participants who received tobramycin inhalation solution (TIS) and oral ciprofloxacin (n = 152) compared with participants who received TIS and oral placebo (n = 152). C, Proportion of participants who were Pseudomonas aeruginosa positive at each study visit comparing participants who received cycled therapy (n = 152) with participants who received culture-based therapy (n = 152). D, Participants who received TIS and oral ciprofloxacin (n = 152) compared with participants who received TIS and oral placebo (n = 152).

Figure 3. Efficacy outcomes. A, Proportion of participants remaining free of exacerbations requiring intravenous antibiotics or hospitalization over time, comparing participants who received cycled therapy (n = 152) with participants who received culture-based therapy (n = 152). B, Participants who received tobramycin inhalation solution (TIS) and oral ciprofloxacin (n = 152) compared with participants who received TIS and oral placebo (n = 152). C, Proportion of participants who were Pseudomonas aeruginosa positive at each study visit comparing participants who received cycled therapy (n = 152) with participants who received culture-based therapy (n = 152). D, Participants who received TIS and oral ciprofloxacin (n = 152) compared with participants who received TIS and oral placebo (n = 152).

The primary end points across all 4 treatment groups are in the eFigure.


Seventy of 152 participants (46%) in the cycled therapy group vs 81 of 152 (53%) in the culture-based group experienced a PE requiring any (intravenous, inhaled, or oral) antibiotics or hospitalization (HR, 0.80; 95% CI, 0.58-1.11) (Table 2). Eighty-three of 152 participants (55%) in the ciprofloxacin group vs 68 of 152 participants (45%) in the placebo group experienced a PE requiring any antibiotics or hospitalization (HR, 1.29; 95% CI, 0.94-1.78) (Table 2).

Table 2. Summary of Primary and Secondary Outcome Variables
Summary of Primary and Secondary Outcome Variables

The majority of participants had negative culture results throughout the study (Table 2), and among those who had positive results, the majority had no more than 2 P aeruginosa– positive cultures. The proportion of participants who had negative results at the end of the study in the cycle- and culture-based groups was not different. Emergence of mucoid strains of P aeruginosa appeared in 5 of 136 participants (3.7%) in the cycled arm and 6 of 143 (4.2%) in the culture-based arm and 6 of 141 (4.2%) vs 5 of 138 (3.6%) in the ciprofloxacin and placebo groups, respectively (eTable 3). Overall, the emergence of tobramycin or ciprofloxacin resistance ranged from 0% to 4% across treatment groups without significant differences by treatment (eTable 3). New isolation of other CF pathogens was not different across treatment groups. Although not different between groups, there was a nonnegligible new isolation of Stenotrophomonas maltophilia in 29 of 138 cycled-treated participants (21%) and 26 of 141 culture-based–treated participants (18.4%) and 29 of 137 (21.2%) vs 26 of 142 (18.3%) in the ciprofloxacin vs placebo group, respectively.

Age-adjusted longitudinal regression models for the estimation of the 18-month rate of change in height and weight showed no statistically significant differences between treatments (Table 2). Among participants able to perform spirometry, the 18-month rate of change in forced expiratory volume in 1 second showed no significant differences comparing the cycled (n = 73) vs culture-based (n = 70) groups or between the ciprofloxacin (n = 67) vs placebo (n = 76) groups (Table 2).


No significant differences in the occurrence of adverse events or serious adverse events were identified in the cycled vs culture-based arm (eTable 4), with the exception of participants assigned to oral ciprofloxacin (whether cycled or culture-based therapy), who demonstrated a greater frequency of symptoms of cough. Throughout the study, renal function, liver function, or blood cell counts were not statistically different among treatment groups. Likewise, no statistical differences were seen between groups in results of musculoskeletal examination (n = 304) or audiometric testing (n = 212).


Although several randomized trials demonstrated eradication of P aeruginosa from the respiratory tract of patients with CF who have recently acquired the bacterium,16-20 to our knowledge, the current study is the first to compare the effect of different therapeutic approaches. We found no statistically significant difference in terms of a reduction in PEs, growth rate, and pulmonary function between cycled quarterly TIS compared with treatment based on microbiological findings. Additionally, we were unable to detect differences in these clinical outcomes by adding a second antibiotic, oral ciprofloxacin. There was no difference in the proportion of P aeruginosa– positive cultures across the 4 treatment groups by the end of the study.

The study did not focus on a formal economic evaluation of treatment options, patient satisfaction, time spent receiving therapy, and overall burden to the family. However, participants randomized to the cycled therapy treatment arms received, on average, 5 additional 28-day treatment cycles of tobramycin or 280 additional inhalation treatments (15-20 minutes per treatment) over the 18 months compared with the culture-based group. Because there was no significant difference in hospitalizations or other measures of clinical benefit and given the low rates of exacerbations, it would be difficult to justify this additional treatment burden. This observation is supported by recent data suggesting that a single 28-day cycle is as effective as a 56-day cycle in clearing P aeruginosa from the airway, with a median time to recurrence of over 2 years.16 The present investigation focused extensively on the systematic evaluation of the safety profile of the different regimens and impact on bacterial resistance. The incidence of treatment-emergent resistance of P aeruginosa to tobramycin and ciprofloxacin was low, ranging from 0% to 4%. Because P aeruginosa recurrence was rare, it was not possible to test many isolates for antibiotic susceptibility. Although not different between groups, we observed emergence of a tobramycin-resistant, gram-negative pathogen S maltophilia in up to 20% of study participants. This frequency is concerning, but the clinical significance of this finding and this pathogen is unclear. S maltophilia has been observed in other studies of inhaled antibiotics,37 without suggestion of an accelerated decline in lung function, at least in older patients with CF chronically colonized with P aeruginosa.38 However, a recent study concluded that chronic S maltophilia detection in patients with CF is a risk factor for PEs.39

While not statistically significant, there was a trend toward more respiratory adverse events (increased cough) in participants assigned to receive ciprofloxacin. Considering that this finding was observed in the context of several secondary analyses, additional research is needed to address these potential concerns. Musculoskeletal adverse effects and hearing abnormalities were not increased.

Conduct of a large, randomized therapeutic trial in young children with CF was challenging. First, the duration of treatment and time commitment of families could have affected study attrition and study compliance. Fortunately, the attrition rate was remarkably low (<10%) and compliance with drug administration was excellent (>90%) in all treatment groups, minimizing bias from loss to follow-up or attenuation of effect size. Second, established clinical outcomes used in CF therapeutic trials involving older participants37,40,41 cannot be reproducibly collected in young children. For example, only 47% of study children were able to perform pulmonary function testing.35 Thus, forced expiratory volume in 1 second could not be used as a primary end point. In addition, only 6% of children were able to expectorate sputum, which is the optimal measure of lower airway infection.42 Thus, oropharyngeal cultures were collected to monitor microbiologic status, a method that is standard clinical practice in asymptomatic patients across the United States.43 We acknowledge that oropharyngeal cultures are a less sensitive measure of lower airway bacterial infection but we could not justify the increased risk or cost of repeated bronchoscopy in this population.44

Quiz Ref IDThe trial was conducted at multiple and widespread geographic sites across the United States, with a population enrolled in the study representing approximately 60% of all eligible patients in the United States.45 Despite enrolling a large proportion of eligible patients and allowing a long follow-up period, the study might have been unable to detect modest differences between the treatment arms. Nonetheless, this study remains one of the largest trials ever conducted in this young CF population. The rate of hospitalizations for respiratory symptoms was lower (0.17 person-year) than observed in the Cystic Fibrosis Patient Registry (0.36 person-year) during study planning. The lack of a placebo group limits our ability to detect a true effect of the study treatments. Over the past decade, the Cystic Fibrosis Foundation care guidelines have recommended quarterly microbiology cultures for all patients.43 This increased surveillance may have resulted in earlier institution of oral antibiotics for respiratory symptoms, affecting the frequency of respiratory-related hospitalizations. All antibiotic use for acute respiratory symptoms (87%) was higher than intravenous antibiotic (21%) administration, with no difference across groups. Two comparative groups are being analyzed for the primary end points, a historic control of children with CF enrolled in an epidemiology study46 from 1990 to 2000 with similar eligibility criteria and a concurrent cohort of patients who became P aeruginosa positive during this trial but chose not to enter the clinical trial.47

This report is an important step in understanding the optimal treatment of early P aeruginosa infection in CF. While not definitive regarding which treatment approach is optimal, the results of the trial provide well-controlled data and suggest little difference in clinical impact across treatment regimens. However, further understanding of the long-term clinical impact and safety of early antibiotic treatment will require additional studies. Study participants were enrolled in a 10-year observational study (89% enrolled) to collect long-term microbiologic, pulmonary function, growth, and hospitalization outcomes.

In conclusion, the approach of administering TIS at the time of recently documented isolation of P aeruginosa in the respiratory tract of children with CF resulted in similar success in maintaining participants free from PEs over an 18-month period, compared with a prophylactic antipseudomonal treatment strategy. Therefore, providing treatment based on a cycled, quarterly schedule is not supported by the results of this trial. The addition of oral ciprofloxacin did not confer additional protection with respect to PEs, microbiological eradication, or other clinical outcomes. These data also indicate that young children recently acquiring P aeruginosa have a high likelihood of eradication with antibiotic therapy and a prolonged period until reemergence of the pathogen. Based on these findings, judicious use of TIS with close microbiologic monitoring of airway cultures in young patients with CF recently infected with P aeruginosa is recommended.

Box Section Ref ID
EPIC Participating Centers and Investigators


Robert J. Beall, Preston W. Campbell III, Bruce C. Marshall.


Wayne Gabbert, Daniel Klein, Kevin Smith, Jim Stone.


Erica Crilly, Kwei Leong.


Lynne Quittell (chair), Columbia University; William R. Clarke, University of Iowa; Mary Jane Kennedy, Virginia Commonwealth University; Kenneth N. Olivier, National Institute of Allergy and Infectious Disease; Ronald C. Rubenstein, Children's Hospital of Philadelphia; O. Dale Williams, University of Alabama at Birmingham; Gail G. Weinmann, executive secretary, National Heart, Lung, and Blood Institute; Susan Banks-Schlegel, National Heart, Lung, and Blood Institute.


George Retsch-Bogart (chair), University of North Carolina at Chapel Hill; Susan Banks-Schlegel, National Heart, Lung, and Blood Institute; Robert J. Beall, Cystic Fibrosis Foundation; Preston W. Campbell, Cystic Fibrosis Foundation; Ron L. Gibson, University of Washington; Gavin R. Graff, The Penn State Milton S. Hershey Medical Center; Hector H. Gutierrez, The University of Alabama at Birmingham; Jamshed Kanga, University of Kentucky; Richard Kronmal, University of Washington; Robert Kuhn (ad hoc), University of Kentucky; Thomas Lahiri, Vermont Children's Hospital at Fletcher Allen Health Care; Nicole Mayer-Hamblett, University of Washington; Catherine McKeon, National Institute of Diabetes and Digestive and Kidney Diseases; Wayne Morgan, University of Arizona; Blakeslee E. Noyes, Saint Louis University/Cardinal Glennon Children's Medical Center; Bonnie W. Ramsey, University of Washington; Margaret Rosenfeld, University of Washington; Lisa Saiman (ad hoc), Columbia University Medical Center; Michael S. Schechter, Emory University; Dennis C. Stokes, Dartmouth-Hitchcock Medical Center; Jeffrey S. Wagener, The Children's Hospital; Judy Williams, CFFT Therapeutics Development Network Coordinating Center.


CRA/study monitors: Clare Castro, Deborah Chambers, Amy Feldman, Robin Hill, Tamara Potter, Sarah Velde; study managers: Shirley Desmon, Amanda Nelson, Judy Williams; clinical trials unit manager: Barbra Fogarty; data management: Barbara Mathewson, Trudi White; statisticians: Umer Khan, Steve Knutzen, Nicole Mayer-Hamblett; study pharmacist: Morty Cohen; quality assurance: Cheryl Kruesel, Dolores Seefried, Anna Wharton; network development: Natalie Beauchene, Lisya Van Housen; regulatory: Lynne Larson; finance: Donna Crist, Chris Fitzpatrick, Sherryl Singleton; microbiology core lab: Anne Marie Buccat, Jane Burns; medical monitors: Christopher Goss.


Akron Children's Hospital/Children's Hospital Medical Center of Akron, Akron, Ohio: site investigators (SI): Nathan C. Kraynack, Gregory Omlor, Kimberly A. Spoonhower; research coordinators (RC): Deborah A. Ouellette; Albany Medical College, Albany, New York: SI: Paul G. Comber; RC: Julie Pursel; Alfred I. duPont Hospital for Children, Wilmington, Delaware: SI: Aaron Chidekel; RC: Sandra M. Budd; All Children's Hospital, St. Petersburg, Florida: SI: Magdalen Gondor; RC: Stasia Lehmann; Children's Hospital Boston, Boston, Massachusetts: SI: Lindo Terry Spencer; RC: Erin Leone Thakkallapalli; Children's Hospital Los Angeles, Los Angeles, California: SI: Arnold C. G. Platzker; Children's Hospital of Michigan Wayne State University, Detroit: SI: Ibrahim Abdulhamid; RC: Catherine Van Wagnen; Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania: SI: David Orenstein; RC: Judy Fulton, Sandy Hurban; Children's Hospital of Wisconsin/Medical College of Wisconsin, Milwaukee: SI: William Gershan; RC: Tami Miller; Children's Hospitals and Clinics of Minnesota, Minneapolis: SI: Michael Pryor; RC: Sandy Landvik, Mary Sachs; Children's Memorial Medical Center, Chicago, Illinois: SI: Adrienne Prestridge; Children's Mercy Hospital, Kansas City, Missouri: SI: Philip Black; RC: Lora Bear; Cook Children's Health Care System, Fort Worth, Texas: SI: Maynard C. Dyson, Karen D. Schultz; RC: Sara Scott; Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire: SI: H. Worth Parker; Emory University, Atlanta, Georgia: SI: Michael S. Schechter; RC: Jeannette Peabody; Helen DeVos Children's Hospital, Grand Rapids, Michigan: SI: Susan L. Millard, John N. Schuen; RC: Teri L. Crumb, Tom Symington; Indiana University/Riley Hospital for Children, Indianapolis: SI: Michelle Howenstine; RC: Terry Barclay; Kaiser Permanente Medical Center, Oakland, California: SI: Greg Shay; RC: Julie Lee; Lucile Packard Children's Hospital/Stanford University, Palo Alto, California: SI: Richard Moss; RC: Colleen Dunn, Zoe Davies; Maine Medical Center, Portland: SI: Anne Marie Cairns, Thomas Mellow; RC: Mary Ellen Corrigan; Massachusetts General Hospital, Boston: SI: Allen Lapey; Medical College of Georgia, Augusta: SI: Margaret F. Guill, Katie McKie; Memorial Miller Children's Hospital, Long Beach, California: SI: Felice Adler-Shohet; RC: Nan O'Donnell; Monmouth Medical Center, Long Branch, New Jersey: SI: Robert L. Zanni; RC: Bridget Marra; Nationwide Children's Hospital, Columbus, Ohio: SI: Karen S. McCoy; Nemours Children's Clinic, Jacksonville, Florida: SI: David A. Schaeffer; RC: Donna L. Pingel, Rena A. Sprinkle; New York Medical College, Valhalla: SI: Nikhil Amin, Allen J. Dozor; RC: Ingrid Gherson; Oregon Health Sciences University, Portland: SI: Michael Wall; Rainbow Babies and Children's Hospital, Cleveland, Ohio: SI: Michael Konstan; RC: Colette Bucur, Cheryl Velotta; Seattle Children’s, Seattle, Washington: SI: Ronald L. Gibson, Margaret Rosenfeld; RC: Sharon McNamara; St. Christopher's Hospital for Children, Philadelphia, Pennsylvania: SI: Laurie Varlotta; St Louis University/Cardinal Glennon Children's Medical Center, St Louis: SI: Blakeslee E. Noyes; RC: Vikki L. Kociela; Schneider Children's Hospital, New Hyde Park, New York: SI: Joan DeCelie-Germana; RC: Lynn Bonitz; SUNY Upstate Medical University, Syracuse, New York: SI: Ran D. Anbar; RC: Donna M. Linder, Valoree N. Suttmore; Texas Children's Hospital, Houston: SI: Peter W. Hiatt; RC: Charlene Hallmark; The Children's Hospital, Denver, Colorado: SI: Frank J. Accurso, Jeffrey S. Wagener; RC: Shelley A. Mann; The Children's Medical Center of Dayton/Wright State University, Dayton, Ohio: SI: Robert J. Fink, Gary A. Mueller; RC: Sandy R. Bartosik; The Johns Hopkins Medical Institutions, Baltimore, Maryland: SI: Peter J. Mogayzel Jr, Pamela L. Zeitlin; RC: Karen A. Callahan, Carolyn G. Chapman; The PennState Milton S. Hershey Medical Center, Hershey, Pennsylvania: SI: Gavin R. Graff, Michael S. Schwartz; RC: Lisa M. Allwein, Diane M. Kitch; The University of Alabama at Birmingham, Birmingham: SI: Hector H. Gutierrez; RC: Lacrecia Britton, Gina Sabbatini; University of California, San Francisco: SI: Dennis W. Nielson; RC: Diem Tran; University of Iowa, Iowa City: RC: Jean Frauenholtz, Mary Teresi; University of Kentucky College of Medicine, Lexington: SI: Michael I. Anstead, Jamshed F. Kanga; RC: Catherine Dudderar; University of Massachusetts Memorial Health Care, Worcester: SI: Brian P. O’Sullivan; RC: Dawn Baker; University of Michigan, Ann Arbor: SI: Samya Z. Nasr; University of Mississippi Medical Center, Jackson: SI: Kim Adcock; University of Nebraska Medical Center, Omaha: SI: John Colombo; RC: Dee Acquazzino; University of North Carolina at Chapel Hill: SI: George Retsch-Bogart; RC: Carol Barlow, Diane Towle; University of Rochester Medical Center, Rochester, New York: SI: Clement L. Ren; University of Tennessee Health Science Center, Memphis: SI: Robert A. Schoumacher; RC: Barbara A. Culbreath, M. Teresa Knight; University of Utah, Salt Lake City: SI: Barbara Chatfield; RC: Susan Griffiths; University of Virginia, Charlottesville: SI: Deborah K. Froh; RC: Robin Kelly; University of Wisconsin–Madison: SI: Michael J. Rock; RC: Linda Makholm; Vanderbilt Children's Hospital, Nashville, Tennessee: SI: Elizabeth Perkett; RC: Alice Bray; Vermont Children's Hospital at Fletcher Allen Health Care, Burlington: SI: Thomas Lahiri; RC: Sandra Diehl.

Back to top
Article Information

Correspondence: Miriam M. Treggiari, MD, PhD, MPH, Department of Anesthesiology and Pain Medicine, 325 Ninth Ave, Box 359724, Seattle, WA 98104 (treggmm@uw.edu).

Accepted for Publication: April 8, 2011.

Author Contributions: Dr Treggiari had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Treggiari, Mayer-Hamblett, Kulich, Kronmal, Williams, Gibson, Burns, Rosenfeld, and Ramsey. Acquisition of data: Retsch-Bogart, Mayer-Hamblett, Hiatt, Gibson, Spencer, Orenstein, Chatfield, Froh, and Burns. Analysis and interpretation of data: Treggiari, Retsch-Bogart, Mayer-Hamblett, Khan, Kronmal, and Ramsey. Drafting of the manuscript: Treggiari, Retsch-Bogart, Mayer-Hamblett, Khan, Kronmal, Hiatt, Burns, and Ramsey. Critical revision of the manuscript for important intellectual content: Treggiari, Retsch-Bogart, Mayer-Hamblett, Kulich, Kronmal, Gibson, Spencer, Orenstein, Chatfield, Froh, Burns, Rosenfeld, and Ramsey. Statistical analysis: Mayer-Hamblett, Khan, Kulich, and Kronmal. Obtained funding: Treggiari, Mayer-Hamblett, Kronmal, and Ramsey. Administrative, technical, and material support: Retsch-Bogart, Hiatt, Gibson, Spencer, and Burns. Study supervision: Retsch-Bogart, Mayer-Hamblett, Williams, Hiatt, Gibson, Froh, and Ramsey.

Financial Disclosure: Study drugs and devices were supplied free of charge by Novartis Pharmaceutical Corp (TIS) and Bayer Healthcare AG (oral ciprofloxacin and oral placebo); compressors and nebulizers were provided by PARI Respiratory Equipment Inc. Dr Chatfield has had research grants or contracts from Gilead Pharmaceuticals, Vertex Pharmaceuticals, and the Cystic Fibrosis Foundation.

Funding/Support: The research for this article was supported in part by Cystic Fibrosis Foundation grant EPIC0K0, National Heart, Lung, and Blood Institute and National Institute of Diabetes and Digestive and Kidney Diseases grant U01-HL080310, and National Center for Research Resources grants ULI-RR025014-03, 1UL1-RR025744, 1UL1-RR025780, UL1-RR025005, UL1-RR0024979, UL1RR025747, UL1-RR025011, 1UL-RR024975, and M01-RR02172.

Role of the Sponsor: The industry sponsors had no role in the analysis, interpretation, and writing of the manuscript. The National Heart, Lung, and Blood Institute–appointed Data and Safety Monitoring Board played a role in the conduct, collection, management, analysis, and interpretation of the data and reviewed and approved the final manuscript.

This article is featured in the Archives Journal Club. Go here to download teaching PowerPoint slides.

Additional Contributions: Special thanks to families of children with CF who participated in the study and whose dedication to research made the trial possible. Patricia Roush, AuD, provided guidance and consultation on audiometric testing. She received financial compensation for her work.

Döring  G, Conway  SP, Heijerman  HG,  et al.  Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.  Eur Respir J. 2000;16(4):749-767. PubMedGoogle ScholarCrossref
Parad  RB, Gerard  CJ, Zurakowski  D, Nichols  DP, Pier  GB.  Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype.  Infect Immun. 1999;67(9):4744-4750. PubMedGoogle Scholar
Henry  RL, Mellis  CM, Petrovic  L.  Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis.  Pediatr Pulmonol. 1992;12(3):158-161. PubMedGoogle ScholarCrossref
Emerson  J, Rosenfeld  M, McNamara  S, Ramsey  B, Gibson  RL.  Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.  Pediatr Pulmonol. 2002;34(2):91-100. PubMedGoogle ScholarCrossref
Rosenfeld  M, Gibson  RL, McNamara  S,  et al.  Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis.  Pediatr Pulmonol. 2001;32(5):356-366. PubMedGoogle ScholarCrossref
 Cystic Fibrosis Foundation Patient Registry 2008 Annual Data Report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation; 2009.
Burns  JL, Gibson  RL, McNamara  S,  et al.  Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis.  J Infect Dis. 2001;183(3):444-452. PubMedGoogle ScholarCrossref
Costerton  JW, Stewart  PS, Greenberg  EP.  Bacterial biofilms: a common cause of persistent infections.  Science. 1999;284(5418):1318-1322. PubMedGoogle ScholarCrossref
Li  Z, Kosorok  MR, Farrell  PM,  et al.  Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.  JAMA. 2005;293(5):581-588. PubMedGoogle ScholarCrossref
Singh  PK, Schaefer  AL, Parsek  MR, Moninger  TO, Welsh  MJ, Greenberg  EP.  Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms.  Nature. 2000;407(6805):762-764. PubMedGoogle ScholarCrossref
West  SE, Zeng  L, Lee  BL,  et al.  Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors.  JAMA. 2002;287(22):2958-2967. PubMedGoogle ScholarCrossref
Sagel  SD, Gibson  RL, Emerson  J,  et al; Inhaled Tobramycin in Young Children Study Group; Cystic Fibrosis Foundation Therapeutics Development Network.  Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.  J Pediatr. 2009;154(2):183-188. PubMedGoogle ScholarCrossref
Armstrong  DS, Grimwood  K, Carlin  JB, Carzino  R, Olinsky  A, Phelan  PD.  Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis.  Pediatr Pulmonol. 1996;21(5):267-275. PubMedGoogle ScholarCrossref
Dakin  CJ, Numa  AH, Wang  H, Morton  JR, Vertzyas  CC, Henry  RL.  Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis.  Am J Respir Crit Care Med. 2002;165(7):904-910. PubMedGoogle ScholarCrossref
Lee  TW, Brownlee  KG, Conway  SP, Denton  M, Littlewood  JM.  Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.  J Cyst Fibros. 2003;2(1):29-34. PubMedGoogle ScholarCrossref
Ratjen  F, Munck  A, Kho  P, Angyalosi  G, ELITE Study Group.  Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial.  Thorax. 2010;65(4):286-291. PubMedGoogle ScholarCrossref
Valerius  NH, Koch  C, Høiby  N.  Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment.  Lancet. 1991;338(8769):725-726. PubMedGoogle ScholarCrossref
Wiesemann  HG, Steinkamp  G, Ratjen  F,  et al.  Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis.  Pediatr Pulmonol. 1998;25(2):88-92. PubMedGoogle ScholarCrossref
Gibson  RL, Emerson  J, McNamara  S,  et al; Cystic Fibrosis Therapeutics Development Network Study Group.  Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.  Am J Respir Crit Care Med. 2003;167(6):841-849. PubMedGoogle ScholarCrossref
Frederiksen  B, Koch  C, Høiby  N.  Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.  Pediatr Pulmonol. 1997;23(5):330-335. PubMedGoogle ScholarCrossref
Munck  A, Bonacorsi  S, Mariani-Kurkdjian  P,  et al.  Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization.  Pediatr Pulmonol. 2001;32(4):288-292. PubMedGoogle ScholarCrossref
Taccetti  G, Campana  S, Festini  F, Mascherini  M, Döring  G.  Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.  Eur Respir J. 2005;26(3):458-461. PubMedGoogle ScholarCrossref
Langton Hewer  SC, Smyth  AR.  Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.  Cochrane Database Syst Rev. 2009;(4):CD004197PubMedGoogle Scholar
Döring  G, Hoiby  N, Consensus Study Group.  Early intervention and prevention of lung disease in cystic fibrosis: a European consensus.  J Cyst Fibros. 2004;3(2):67-91. PubMedGoogle ScholarCrossref
Treggiari  MM, Rosenfeld  M, Retsch-Bogart  G, Gibson  R, Ramsey  B.  Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis.  Pediatr Pulmonol. 2007;42(9):751-756. PubMedGoogle ScholarCrossref
Lee  TW.  Eradication of early Pseudomonas infection in cystic fibrosis.  Chron Respir Dis. 2009;6(2):99-107. PubMedGoogle ScholarCrossref
Rosenfeld  M, Emerson  J, Williams-Warren  J,  et al.  Defining a pulmonary exacerbation in cystic fibrosis.  J Pediatr. 2001;139(3):359-365. PubMedGoogle ScholarCrossref
Pamukcu  A, Bush  A, Buchdahl  R.  Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis.  Pediatr Pulmonol. 1995;19(1):10-15. PubMedGoogle ScholarCrossref
Hansen  CR, Pressler  T, Høiby  N.  Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.  J Cyst Fibros. 2008;7(6):523-530. PubMedGoogle ScholarCrossref
Treggiari  MM, Rosenfeld  M, Mayer-Hamblett  N,  et al; EPIC Study Group.  Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study.  Contemp Clin Trials. 2009;30(3):256-268. PubMedGoogle ScholarCrossref
Rosenstein  BJ, Cutting  GR, Cystic Fibrosis Foundation Consensus Panel.  The diagnosis of cystic fibrosis: a consensus statement.  J Pediatr. 1998;132(4):589-595. PubMedGoogle ScholarCrossref
Bosso  JA.  Use of ciprofloxacin in cystic fibrosis patients.  Am J Med. 1989;87(5A):123S-127S. PubMedGoogle ScholarCrossref
Schaad  UB, Rubio  T, Kanga  J, Stutman  HR, Smith  A.  Panel discussion: antimicrobial therapy in pediatric cystic fibrosis patients.  Pediatr Infect Dis. 1997;16(1):123-126. 10.1097/00006454-199701000-00035Google ScholarCrossref
Burns  JL, Emerson  J, Stapp  JR,  et al.  Microbiology of sputum from patients at cystic fibrosis centers in the United States.  Clin Infect Dis. 1998;27(1):158-163. PubMedGoogle ScholarCrossref
Beydon  N, Davis  SD, Lombardi  E,  et al; American Thoracic Society/European Respiratory Society Working Group on Infant and Young Children Pulmonary Function Testing.  An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children.  Am J Respir Crit Care Med. 2007;175(12):1304-1345. PubMedGoogle ScholarCrossref
Diggle  PJ, Haegerty  P, Liang  KY, Zeger  SL.  Analysis of Longitudinal Data. 2nd ed. Oxford, England: Oxford University Press; 2002.
Ramsey  BW, Pepe  MS, Quan  JM,  et al; Cystic Fibrosis Inhaled Tobramycin Study Group.  Intermittent administration of inhaled tobramycin in patients with cystic fibrosis.  N Engl J Med. 1999;340(1):23-30. PubMedGoogle ScholarCrossref
Goss  CH, Mayer-Hamblett  N, Aitken  ML, Rubenfeld  GD, Ramsey  BW.  Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis.  Thorax. 2004;59(11):955-959. PubMedGoogle ScholarCrossref
Waters  V, Yau  Y, Prasad  S,  et al.  Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease.  Am J Respir Crit Care Med. 2011;183(5):635-640. PubMedGoogle ScholarCrossref
Fuchs  HJ, Borowitz  DS, Christiansen  DH,  et al; The Pulmozyme Study Group.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis.  N Engl J Med. 1994;331(10):637-642. PubMedGoogle ScholarCrossref
Saiman  L, Marshall  BC, Mayer-Hamblett  N,  et al; Macrolide Study Group.  Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.  JAMA. 2003;290(13):1749-1756. PubMedGoogle ScholarCrossref
Thomassen  MJ, Klinger  JD, Badger  SJ, van Heeckeren  DW, Stern  RC.  Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis.  J Pediatr. 1984;104(3):352-356. PubMedGoogle ScholarCrossref
 Clinical Practice Guidelines for Cystic Fibrosis. Bethesda, MD: Cystic Fibrosis Foundation; 1997.
Rosenfeld  M, Emerson  J, Accurso  F,  et al.  Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis.  Pediatr Pulmonol. 1999;28(5):321-328. PubMedGoogle ScholarCrossref
 Cystic Fibrosis Foundation Patient Registry 1999 Annual Data Report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation; 2000.
Konstan  MW, Butler  SM, Schidlow  DV, Morgan  WJ, Julius  JR, Johnson  CA, Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.  Patterns of medical practice in cystic fibrosis, part II: use of therapies.  Pediatr Pulmonol. 1999;28(4):248-254. PubMedGoogle ScholarCrossref
Rosenfeld  M, Emerson  J, McNamara  S,  et al; EPIC Study Group Participating Clinical Sites.  Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort.  Pediatr Pulmonol. 2010;45(9):934-944. PubMedGoogle ScholarCrossref